PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

The PEOPLE trial aimed to identify new immune biomarkers in negative and low programmed death-ligand 1 (PD-L1) (0%-49%) advanced non-small-cell lung cancer (aNSCLC) patients treated with first-line pembrolizumab. Here we report the main outcomes and the circulating immune biomarkers analysis

NA62 results on Dark Sector searches

NA62 is a precision physics experiment studying charged kaons and their decayproducts with an unprecedented accuracy (measurement of the K + → π + ννbranching ratio of the order of 10 −11), allowing indirect probes of new physicsscales up to O(100) TeV. NA62 experiment also searches directly for weaklyinteracting particles of up to O(100) MeV masses in kaon decays and up to O(1)GeV masses when running in the beam dump mode. For both modes of directsearches, NA62 has been collecting data since 2021 after a successful 2016-18run 1. Past results and future prospects are presented in this talk